Genmab has announced a tender offer to acquire 100% of Merus N.V., aiming to enhance its therapeutic pipeline and strengthen its position in the biotechnology industry.
Target Information
Merus N.V., based in Utrecht, The Netherlands, is a biotechnology company focused on the development of innovative, dual-specific therapeutics. Known for its proprietary technology platform, Merus is engaged in advancing a promising pipeline of bispecific antibody candidates aimed at treating various forms of cancer. The company has established a reputation for its cutting-edge research and commitment to addressing unmet medical needs in oncology.
The acquisition of Merus by Genmab is seen as a strategic move to enhance its operational capabilities and provide a fuller spectrum of therapeutic options within its drug development pipeline. With Merus’s innovations and collaborative approaches to research, the combination is positioned to strengthen Genmab's offerings in the competitive biotech sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology industry in the Netherlands is recognized for its robust growth and high level of innovation, driven by a strong focus on research and development. The country is home to numerous biotech comp
Similar Deals
Genmab
invested in
Merus
in 2025
in a Buyout deal
Disclosed details
Transaction Size: $5,500M